Head & Neck Cancer Drugs Market Perceptions Targeting Industrial Expansion Studied during the Forecast Period, 2018-2025
December 5, 2019 by Mike Williams
The global head & neck cancer drugs market was valued at $1,295 million in 2017, and is projected to reach $2,281 million by 2025, registering a CAGR of 7.3% from 2018 to 2025.
Head & neck cancers include a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses, lips, salivary glands and mouth. Head and neck squamous cell carcinoma (HNSCC) is the most common form of head & neck cancer, which develops in the mucous membranes of the mouth, nose, and throat. Chemotherapy, immunotherapy & targeted therapy are used for the treatment of head & neck cancer along with the radiation & surgical procedures.
Get Report Sample Copy for Detailed Insights @ https://www.factomarketinsights.com/sample/233
There is an increase in the demand for head & neck cancer drugs owing to the growth in incidence of head & neck cancer, rise in demand for combination therapeutics, higher number of R&D studies, and surge in adoption of immune therapeutics. In addition, growth in the geriatric population and technological advancements in screening & diagnosis of head & neck cancer further drive the market growth. Strong presence of late-stage pipeline drugs such as Ipilimumab, Atezolizumab, Avelumab, Durvalumab, Erlotinib, Afatinib, Bevacizumab, and others are expected to drive the market growth. However, higher cost & adverse effect associated with head & neck cancer drugs are projected to impede the market growth.
The global head & neck cancer drugs market is segmented based on drug class, sales channel, and region. Based on drug class, the market is classified as chemotherapy, immunotherapy, and targeted therapy. According to the sales channel, the market is categorized as hospital pharmacies, drug stores and retail pharmacies, and online stores. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and rest of LAMEA).
Key Benefits for Head & Neck Cancer Drugs Market:
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
Browse Complete Research Report with TOC @ https://www.factomarketinsights.com/report/233/head-&-neck-cancer-drugs-market-amr
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
Head & Neck Cancer Drugs Key Market Segments:
By Drug Class
By Sales Channel
Request for Sample Report @ https://www.factomarketinsights.com/sample/233
List of Key Players Profiled in the Report:
Facto market insights is one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends.
Our in-house research experts have a wealth of knowledge in their respective domains. With Facto Market Research, you always have the choice of getting customized report free of cost (upto 10%). Our support team will help you customize the report and scope as per your business needs. This ensures that you are making the right purchase decision.
150 State St.
Tel: +1 518-300-1215